Sling Therapeutics announces topline efficacy and safety data from Phase 2b/3 LIDS trial on linsitinib
Linsitinib is being evaluated in patients with active, moderate to severe thyroid eye disease (TED).
HelpMeSee announces new training partnerships, simulation training sites
(VLOG) NeuroOp Guru: Can a dead nerve swell?
Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve can swell, focusing on the condition of papilledema caused by elevated intracranial pressure.
Glaukos announces several positive clinical updates for its iDose platform
The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.
Rayner launches redesign of IOL calculator RayTrace
RayTrace has been utilized globally by surgeons since 2008.
InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease.
Greek researchers report rare case of fungal endophthalmitis
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in 3 cohorts.
Inflammasome Therapeutics expands K8 trial following positive 3-month results
Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.
Cost-effectiveness of AI pediatric eye screening
Cost among other factors may deter patients from screening, especially in rural and low-resource settings.
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.
City Therapeutics and Bausch + Lomb partner on geographic atrophy treatment candidate
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
How food choices may affect non-refractive visual impairment
Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US populations
4DMT releases positive topline interim data from Part 1 of the SPECTRA clinical trial
This trial is designed to evaluate 4D-150 in diabetic macular edema.
RhyGaze secures Series A financing of $86 million to further novel gene therapy
The funding will support activities like formal pharmacology and toxicology testing.
Ashvattha Therapeutics secures $50M in financing to advance clinical trials
The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME
Ocugen announces positive 2-year safety and efficacy update of Phase 1/2 OCU400 for treatment of retinitis pigmentosa
OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.
Snowmass Retina and Eye 2025: Ronald Frenkel, MD, previews interactive learning and innovation amid winter fun
Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, all set against the backdrop of Snowmass, Colorado.
Bausch + Lomb launches its enVista Aspire monofocal and toric IOLs in the European Union
The launch follows a CE Mark received late last year.
Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery
4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME
The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.
FDA approves Zeiss MEL 90 excimer laser
With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.
Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)
Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).
Bausch + Lomb acquires Whitecap Biosciences
Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.
Multiple companies appoint new leadership across the industry
Several companies have announced new executives and board members appointments as they prepare for growth in 2025.
VLOG: NeuroOp Guru: Can AI distinguish between papilledema and optic disc drusen using color fundus photos?
Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss deep learning systems and whether they can distinguish between optic disc drusen and true papilledema
Study reveals link between hypoxia and nAMD
New research links retinal imaging and deep learning to improved schizophrenia detection
Eyebright Medical receives Class III Certificate from National Medical Products Administration in China for its phakic intraocular lens
The Loong Crystal PR IOL is designed for the treatment of myopia in adults ranging from -3.25D to -18.00D.
FDA accepts revised supplemental New Drug Application for IZERVAY
The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.
